Propentofylline reverses delayed remyelination in streptozotocin-induced diabetic rats

Abstract

Objective

The diabetic state induced by streptozotocin injection is known to impair oligodendroglial remyelination in the rat brainstem following intracisternal injection with the gliotoxic agent ethidium bromide (EB). In such experimental model, propentofylline (PPF) recently showed to improve myelin repair, probably due to its neuroprotective, antiinflammatory and antioxidant effects. The aim of this study was to evaluate the effect of PPF administration in diabetic rats submitted to the EB-demyelinating model.

Materials and methods

Adult male rats, diabetic or not, received a single injection of 10 microlitres of 0.1% EB solution into the cisterna pontis. For induction of diabetes mellitus the streptozotocin-diabetogenic model was used (50 mg/kg, intraperitoneal route – IP). Some diabetic rats were treated with PPF (12.5 mg/kg/day, IP route) during the experimental period. The animals were anesthetized and perfused from 7 to 31 days after EB injection and brainstem sections were collected for analysis of the lesions by light and transmission electron microscopy.

Results

Diabetic rats injected with EB showed larger amounts of myelin-derived membranes in the central areas of the lesions and considerable delay in the remyelinating process played by surviving oligodendrocytes and invading Schwann cells after the 15^th day. On the other hand, diabetic rats that received PPF presented lesions similar to those of non-diabetic animals, with rapid remyelination at the edges of the lesion site and fast clearance of myelin debris from the central area.

Conclusion

The administration of PPF apparently reversed the impairment in remyelination induced by the diabetic state. Arch Endocrinol Metab. 2015;59(1):47-53

Central nervous system; diabetes mellitus; oligodendrocytes; propentofillyne; remyelination

INTRODUCTION

It is widely described that focal injection of the gliotoxic agent ethidium bromide (EB) in the white matter of the central nervous system (CNS) causes local oligodendroglial and astrocytic death, with consequent primary demyelination, blood-brain barrier disruption and Schwann cell invasion due to the glia limitans breakdown (¹-⁶). Hyperglycemia found in diabetes mellitus is known to cause well described morphological and functional changes in peripheral neurons and Schwann cells (⁷). Much less is understood about the effects of hyperglycemia on CNS cells, mainly on glia. It is recognized that diabetes exacerbated astrocytic (⁸,⁹) and neuronal (¹⁰,¹¹) damage induced by ischemia and reperfusion. On the other hand, insulin treatment prevented diabetes-induced alterations in astrocyte glutamate uptake and reverted the decreased GFAP expression in rats at 4 and 8 weeks of diabetes duration (¹²). Glial modifications were clearly pointed in some studies using streptozotocin-diabetic rats after the injection of EB (¹³-¹⁵), with marked delay on macrophagic scavenging activity of myelin debris, on oligodendrocyte and Schwann cell remyelination (¹³), on blood-brain barrier repair (¹⁴) as well as on glial fibrillary acidic protein (GFAP) expression in reactive astrocytes at the periphery of the injury site (¹⁵).

Several in vitro and in vivo studies have shown that propentofylline [PPF, 3-methyl-1-(5’-oxohexyl)-7-propylxanthine], a xanthine derivative, presents profound neuroprotective, antioxidant and anti-inflammatory effects (¹⁶,¹⁷). Clinically it has shown efficacy in degenerative vascular dementia (¹⁸) and as a potential adjuvant treatment to Alzheimer’s disease (¹⁹,²⁰), schizophrenia (²¹) and multiple sclerosis (²²). PPF probably depresses activation of microglial cells and astrocytes, which is associated with neuronal damage during inflammation and hypoxia and consequently decreases glial production and release of damaging proinflammatory factors (¹⁶). In the EB demyelinating model, PPF administration after gliotoxic injection significantly increased both oligodendroglial and Schwann cell remyelination at 31 days (²³).

Thus, the aim of this investigation was to evaluate if PPF had the capacity of improving activity of myelinogenic cells in diabetic rats following EB gliotoxic injury.

MATERIALS AND METHODS

This experiment was approved by the Ethics Comission of the Universidade Paulista (protocol number 023/11). Forty-eight adult (4-6 month old) male Wistar rats were used and 32 animals received, after a period of fasting of 12 hours, a single injection of streptozotocin (50 mg/kg, Sigma) in 0.01M citrate buffer (pH 4.5) by intraperitoneal (IP) route. Ten days after blood glucose level was measured and animals with levels of 300 mg/dL or more were considered diabetic. At this time they were submitted to a local injection of 10 microlitres of 0.1% EB into the cisterna pontis. All rats were anaesthetized with ketamine and xylazine (5:1; 0.1 ml/100 g) and 2.5% thiopental (40 mg/kg) by IP route and a burr-hole was made on the right side of the skull, 8 mm behind the fronto-parietal suture. Injections were performed freehand using a Hamilton Syringe, fitted with a 35^o angled polished 26 gauge needle into the cisterna pontis, an enlarged subarachnoid space below the ventral surface on the pons. Diabetic rats were then distributed into two groups – untreated rats (group I, n = 16) and rats treated with 12.5 mg/kg/day of PPF (Agener União Química, São Paulo, SP, 20 mg/mL solution) by IP route during the experimental period (group II, n = 16). Non-diabetic rats which also received an intracisternal injection of 10 microlitres of EB formed a third group (group III, n = 16).

Body weight and blood glucose levels (Dextrostix, Ames) were recorded at 3 times – at the moment of the streptozotocin injection, at the moment of the EB injection and at the time of euthanasia. The animals were kept under controlled light conditions (12 h light-dark cycle) and water and food were given ad libitum during the experimental period. Four rats were anaesthetized and were submitted to intracardiac perfusion with 4% glutaraldehyde in 0.1 M Sorensen phosphate buffer (pH 7.4) at each of the following periods - 7, 15, 21 and 31 days post-injection (p.i.). Thin slices of the brainstem (pons and mesencephalon) were collected and post-fixed in 0.1% osmium tetroxide, dehydrated with graded acetones and embedded in Araldite 502 resin, following transitional stages in acetone. Thick sections were stained with 0.25% alkaline toluidine blue. Selected areas were trimmed and thin sections were stained with 2% uranyl and lead acetate and viewed in a JEM -1200 EX2 JEOL transmission electron microscope.

RESULTS

Clinical observations of diabetic rats

All rats submitted to the streptozotocin injection presented hyperglycemia (levels from 320 to 730 mg/dL) at the 10^th day and at perfusion day. During the experimental period they developed characteristic polyuria, polydipsia and body weight loss. Plasma glucose levels and body weight data are shown in table 1.

Table 1
Body weights and plasma glucose levels of the experimental groups

	Group I	Group II	Group III
Day -10	(16)	(16)	(16)
BW (g)	268.4 ± 7.8	270.1 ± 4.5	266.6 ± 6.9
PG (mg/dL)	133.2 ± 8.3	139.7 ± 7.6	135.7 ± 5.3
Day 0	(16)	(16)	(16)
BW (g)	254.5 ± 6.5	256.6 ± 7.2	275.3 ± 8.3
PG (mg/dL)	382.4 ± 10.1	346.2 ± 8.9	130.3 ± 11.9
Day 7	(4)	(4)	(4)
BW (g)	251.2 ± 15.9	250.3 ± 16.8	278.7 ± 10.4
PG (mg/dL)	450.1 ± 6.3	389.8 ± 4.7	141.7 ± 10.6
Day 15	(4)	(4)	(4)
BW (g)	239.7 ± 4.2	243.7 ± 15.3	285.3 ± 9.5
PG (mg/dL)	433.5 ± 7.4	425.7 ± 10.2	139.5 ± 12.2
Day 21	(4)	(4)	(4)
BW (g)	247.3 ± 7.1	245.4 ± 7.3	313.4 ± 11.7
PG (mg/dL)	490.2 ± 11.4	433.3 ± 8.7	135.7 ± 11.3
Day 31	(4)	(4)	(4)
BW (g)	239.6 ± 14.4	237.5 ± 6.4	340.2 ± 9.7
PG (mg/dL)	469.7 ± 10.2	432.3 ± 8.1	135.7 ± 15.3

• Data are presented as means ± standard deviation (SD) for the number of rats given in parenthesis. Group I – diabetic rats with ethidium bromide (EB) injection; Group II – diabetic rats with EB injection and propentofylline (PPF) treatment; Group III – non-diabetic rats with EB injection. BW: body weight (g); PG: plasma glucose (in mg/dL); Day -10: day of streptozotocin injection in groups I and II; Day 0: day of EB administration in groups I, II and III.

General aspects from EB-induced lesions

The EB-induced lesions were similar to those previously described in the brainstem of diabetic (¹³-¹⁵) and non-diabetic rats (¹-⁶). In general terms, they were characterized by demyelinated areas in the ventral surface of the pons and mesencephalon, containing in the central region phagocytic cells, variable amounts of myelin-derived membranes in a distended extracellular space as well as naked axons. At the periphery, from 15 to 31 days p.i., it was noted the presence of oligodendrocytes and Schwann cells, the latter occurring in areas of enlarged extracellular space devoid of astrocytic extensions, notably around blood vessels and in subpial areas. Astrocyte processes were invariably seen near the incipient oligodendroglial remyelination and Schwann cells were noted in astrocyte-free areas producing thicker sheaths than those formed by oligodendrocytes at the same period. In the central area a variable proportion of axons persisted without myelin until the 31^st day p.i. Few lymphocytes and some infiltrating pial cells were also observed in all periods.

Comparison between EB-induced lesions from groups I, II and III

By 7 days p.i., the examination of semithin and ultrathin sections from diabetic rats from group I revealed the appearance of a larger demyelinated area filled with huge amounts of myelin-derived membranes around naked axons and foamy macrophages when compared with rats from groups II (diabetic rats treated with PPF) and III (non-diabetic rats) at the same period. The quantity of myelin debris was remarkably greater in group I and such difference appeared to increase from 15 to 31 days p.i. (Figure 1A and B) in comparison with the other groups (Figure 1C and D). No astrocytic processes were seen in the central area of the lesions in all groups, but in groups II and III astrocytic processes appeared to be more frequently found at the edges of the injury site after 15 days. At peripheral locations, by day 15 p.i. cells with morphological resemblance to oligodendrocytes were seen over the edges of the lesions, some of them already forming thin myelin sheaths. Schwann cells appeared associated with one or multiple demyelinated axons or already forming thin myelin lamellae around single axons in astrocyte-free areas. Remyelination was a relatively rare finding in diabetic rats from group I even at 31 days p.i. (Figure 2A and B) in relation to groups II and III (Figure 2C and D). Axons with signs of degeneration (Figure 3A and B) persisted until day 31 p.i. in animals from all groups, although a much larger number of degenerating fibers was observed in diabetic rats from group I than in diabetic rats treated with PPF or non-diabetic rats. Pial cell infiltration was noted from 15 to 31 days p.i. in all groups. Differences in remyelination between diabetic rats from group I and diabetic rats treated with PPF or non-diabetic rats from group III clearly appeared from day 15 p.i. as the last two groups presented a greater proportion of oligodendrocyte remyelinated axons when compared to the diabetic ones without PPF. Schwann cell remyelination in diabetic rats was also increased with PPF treatment (Figure 4A and B).

Figure 1
Macrophages (m) in intense phagocytic activity in a central area of the lesion at 15 days after EB injection. Note in (A) and (B) from diabetic rats (group I) the presence of demyelinated axons (d) and the larger quantity of myelin-derived membranes (asterisk) in the extracellular space. (A) Bar = 2 µm; (B) Bar = 1 µm. (C) Group II (diabetic rats treated with PPF); Bar = 3 µm. (D) Group III (non-diabetic rats); Bar = 4 µm.

Figure 2
(A,B) Demyelinated axons (d) persisted among macrophages (m) and myelin-derived membranes (asterisks) at 31 days in diabetic rats from group I despite the presence of oligodendrocytes (O). (A) Bar = 3 µm; (B) Bar = 2 µm. (C,D) Thinly remyelinated axons by oligodendrocytes (O) at 31 days. (C) Group II (diabetic rats treated with PPF); Bar = 2 µm. (D) Group III (non-diabetic rats); Bar = 1 µm.

Figure 3
(A,B) Degenerating axons (arrows) were easily seen in diabetic rats from group I, even among remyelinated axons (arrowheads) at 31 days post-injection. v – blood vessel. (A) Bar = 3 µm; (B) Bar = 2 µm.

Figure 4
(A,B) Schwann cells (S) close to astrocytes (A) and demyelinated (in A) and remyelinated (in B) axons at 31 days following EB injection. (A) Group I (diabetic rats). Bar = 2 µm; (B) Group II (diabetic rats treated with PPF); Bar = 2 µm.

DISCUSSION

Diabetic rats presented lesions similar to those observed in earlier investigations (¹³-¹⁵,²⁴) involving EB injection in streptozotocin-induced diabetes and comparable to those observed in cyclophosphamide immunosuppressed rats (⁵), in which large amounts of myelin debris and demyelinated axons were found as well as delayed remyelination by both oligodendrocytes and Schwann cells. The persistence of myelin-derived membranes in an expanded extracellular space suggested that somehow phagocytic activity was impaired (¹³). Diabetes has also shown to decrease GFAP expression in reactive astrocytes around EB-induced lesions (¹⁵). The mechanisms by which the diabetic state affect CNS glial cells, such as oligodendrocytes, and astrocytes, remain unclear. On the other hand, it is known that hyperglycemia causes intracellular glucose accumulation and increases polyol pathway activity by aldose reductase in cells that do not need insulin for glucose transmembrane transport, such as Schwann cells, thus resulting in increased levels of sorbitol and fructose, a fact that may cause osmotic swelling and even cell death (²⁵). Hyperglycemia may also increase oxidative stress and reactive oxidative species (ROS) generation, initiating apoptotic signaling pathways (²⁶).

It is suggested that the impaired remyelination found in diabetic rats following EB injection may be caused by a lack of trophic factors for proliferation and differentiation of myelinogenic cells, such as surviving oligodendrocytes; their progenitors, the OPCs (oligodendrocyte progenitor cells); and/or invading Schwann cells. Insulin and IGF-1, for example, which are recognized as stimulating factors for Schwann cells (²⁷), are decreased in experimental diabetes (²⁸). IGF-1 and 2 also stimulate OPC proliferation (²⁹) and receptors for IGF-1 are expressed in astrocytes and oligodendrocytes over the edges of demyelinating lesions (³⁰).

As previously observed in non-diabetic rats (²³), PPF administration seemed to increase both oligodendrocyte and Schwann cell remyelination in the rat brainstem of diabetic animals following gliotoxic injury, apparently reversing the deleterious effects of diabetes on remyelination. Known mechanisms of PPF include inhibition of cyclic AMP (cAMP) and cyclic GMP phosphodiesterases (PDE) and action as a reuptake inhibitor for the purine nucleoside and neurotransmitter adenosine by blocking the activity of membrane nucleoside transporters (ENTs). This leads to increased intracellular cAMP levels and greater extracellular concentrations of adenosine (¹⁶), stimulating adenosinergic neurotransmission and adenosine 2 (A²) receptor-mediated cAMP synthesis (³¹,³²).

In the CNS, PPF acts as a glial modulator, with direct actions on microglia, decreasing microglial proliferation and expression of inflammatory cytokines in vitro, such as tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β) (³³,³⁴). Regulation of cytokine production by leukocytes includes the adenylate cyclase – cAMP – protein kinase pathway, which also affects the activity of a great number of other cell types (³⁵).

Intracellular levels of the second messenger cAMP can be increased by adenylate cyclase activation or by cAMP-degrading phosphodiesterases (PDE) inhibition. Elevation of cAMP in leukocytes mainly down-regulates inflammatory and immune responses. Inhibition of secretion of the T helper cell type 1 (Th1) – derived cytokines IL-2, IL-12 and IFN-δ and of TNF-α synthesis has been described for a number of PDE inhibitors (PDEIs), including PPF, and for activators of adenylate cyclase, such as prostaglandins (³⁵).

Yoshikawa and cols. (³⁴) reported that PPF, a type III-IV specific PDEI, although decreasing in a dose-dependent manner the production of the inflammatory cytokines TNF-α, IL-1 and IL-6 by LPS-activated microglial cells in vitro, increased up to three times the production of IL-10, an inhibitory cytokine, which is recognized to impair cytokine production of Th1 lymphocytes. Besides IL-10 also inhibits the activation of macrophages and microglia induced by IFN-δ (³⁴).

It has been hypothesized that inflammatory mediators could create a detrimental environment to myelin and myelinogenic cells with potentially damaging molecules to the neural tissue. Products secreted by macrophages, lymphocytes and astrocytes during the inflammatory reaction to EB may exacerbate the direct damaging effects induced by the gliotoxin. In such context the anti-inflammatory and antioxidant effects performed by PPF may be supportive to myelin repair even in diabetic rats, whose remyelinating capacity is undoubtedly compromised.

A Ca⁺⁺ – dependent and excessive activation of glial cells is involved in neuroinflammation. In cultured microglial cells, several days’ treatment with adenosine agonists or PPF increased apoptosis in activated microglial cells and strongly inhibited the secretion of pro-inflammatory substances and the formation of ROS, as well as their transformation into macrophages after injury (³¹,³²). Probably by affecting Ca⁺⁺ - and cAMP-dependent molecular signaling pathways, PPF stimulates the production of trophic factors in astrocytes, apparently avoiding a harmful and secondary astrocytic activation caused by previous microglial up-regulation.

Diabetic rats treated with PPF presented lesions that resembled those observed with cyclosporine treatment following streptozotocin-induced diabetes (²⁴), with a higher density of oligodendrocytes over the edges of the lesions and increased remyelination. The precise mechanisms by which the beneficial effects of PPF occur in diabetic rats remain obscure, although it has been believed that drugs that elevate extracellular adenosine and/or block the degradation of cyclic nucleotides, like PPF, may explain the improvement of remyelination.

Acknowledgements

This study was supported by National Counsel of Technological and Scientific Development (CNPq).

REFERENCES

• ¹
  Yajima K, Suzuki K. Ultrastructural changes of oligodendroglia and myelin sheaths induced by ethidium bromide. Neuropathol Appl Neurobiol. 1979;5:49-62.
• ²
  Blakemore WF. Ethidium bromide induced demyelination in the spinal cord of the cat. Neuropathol Appl Neurobiol. 1982;8:365-75.
• ³
  Graça DL, Bondan EF, Pereira LAVD, Fernandes CG, Maiorka PC. Behaviour of oligodendrocytes and Schwann cells in an experimental model of toxic demyelination of the central nervous system. Arq Neuropsiquiatr. 2001;59:358-61.
• ⁴
  Pereira LAVD, Dertkigill MS, Graça DL, Cruz-Höffling MA. Dynamics of remyelination in the brain of adult rats after exposure to ethidium bromide. J Submicrosc Cytol Pathol. 1998;30:341-8.
• ⁵
  Bondan EF, Lallo MA, Sinhorini IL, Pereira LAVD, Graça DL. The effect of cyclophosphamide on the rat brainstem remyelination following local ethidium bromide injection in Wistar rats. J Submicrosc Cytol Pathol. 2000;32:603-12.
• ⁶
  Bondan EF, Lallo MA, Dagli MLZ, Pereira LAVD, Graça DL. Blood-brain barrier breakdown following gliotoxic drug injection in the brainstem of Wistar rats. Arq Neuropsiquiatr. 2002;60:582-9.
• ⁷
  Vincent AM, Kato K, McLean LL, Soules ME, Feldman EL. Sensory neurons and Schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal. 2009;11:425-38.
• ⁸
  Li P, Ding C, Muranyi M, He Q, Lin Y. Diabetes mellitus causes astrocyte damage after ischemia and reperfusion injury. J Cereb Flow and Metab. 2005;25:S430.
• ⁹
  Muranyi M, Ding C, He Q, Lin Y, Li P. Streptozotocin-induced diabetes causes astrocyte death after ischemia and reperfusion injury. Diabetes. 2006;55:349-55.
• ¹⁰
  Li PA, Siesjo BK. Role of hyperglycaemia-related acidosis in ischaemic brain damage. Acta Physiol Scand. 1997;161:567-80.
• ¹¹
  Li PA, Gisselsson L, Keuker J, Vogel J, Smith MI, Kuschinsky W, et al. Hyperglycemia exaggerated ischemic brain damage following 30 min of middle cerebral artery occlusion due to capillary obstruction. Brain Res. 1998;804:36-44.
• ¹²
  Coleman ES, Dennis JC, Braden TD, Judd RL, Posner P. Insulin treatment prevents diabetes-induced alterations in astrocyte glutamate uptake and GFAP content in rats at 4 and 8 weeks of diabetes duration. Brain Res. 2010;8:131-41.
• ¹³
  Bondan EF, Lallo MA, Trigueiro AH, Ribeiro CP, Sinhorini IL, Graça DL. Delayed Schwann cell and oligodendrocyte remyelination after ethidium bromide injection in the brainstem of Wistar rats submitted to streptozotocin diabetogenic treatment. Braz J Med Biol Res. 2006;39:637-46.
• ¹⁴
  Bondan EF, Martins MFM. Blood-brain barrier breakdown and repair following gliotoxic drug injection in the brainstem of streptozotocin-diabetic rats. Arq Neuropsiquiatr. 2012;70:221-5.
• ¹⁵
  Bondan EF, Martins MFM, Viani FC. Decreased astrocytic GFAP expression in streptozotocin-induced diabetes after gliotoxic lesion in the rat brainstem. Arq Bras Endocrinol Metab. 2013;57:431-6.
• ¹⁶
  Sweitzer S, De Leo J. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Handb Exp Pharmacol. 2011;200:235-50.
• ¹⁷
  Koriyama Y, Chiba K, Mohri T. Propentofylline protects β-amiloid protein-induced apoptosis in cultured rat hipocampal neurons. Eur J Pharmacol. 2003;458:235-41.
• ¹⁸
  Kittner B, Rössner M, Rother M. Clinical trials in dementia with propentofylline. Ann N Y Acad Sci. 1997;826:307-16.
• ¹⁹
  Bachynsky J, McCracken DL, Alloul K, Jacobs P. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord. 2000;14:102-11.
• ²⁰
  Wilkinson D. Drugs for treatment of Alzheimer’s disease. Int J Clin Pract. 2001;55:129-34.
• ²¹
  Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 726-32.
• ²²
  Suzumura A, Nakamuro T, Tamaru T, Takayanagi T. Drop in relapse rate of MS combination therapy of three different phosphodiesterase inhibitors. Mult Scler. 2000;6:56-8.
• ²³
  Bondan EF, Martins MMF, Baliellas DEM, Gimenez CFM, Poppe SC, Bernardi MM. Effects of propentofylline on CNS remyelination in the rat brainstem. Microsc Res Tech. 2014;77:23-30.
• ²⁴
  Bondan EF, Martins MFM. Cyclosporine improves remyelination in diabetic rats submitted to a gliotoxic demyelinating model in the brainstem. Microsc Res Tech. 2013;76:714-22.
• ²⁵
  Cotran RS, Kumar V, Collins SL. Robbins – Pathologic basis of disease. Philadelphia: WB Saunders; 2000. p. 691-706.
• ²⁶
  Ahmadpour S. CNS complications of diabetes mellitus type 1 (type 1 diabetic encephalopathy). In: Oguntibeju OO. Pathophysiology and complications of diabetes mellitus. Rijeka: In Tech; 2012. p. 1-18.
• ²⁷
  Schumacher M, Jung-Testas I, Robel P, Baulieu EE. Insulin-like growth factor I: a mitogen for rat Schwann cells in the presence of elevated levels of cyclic AMP. Glia. 1994;8:232-40.
• ²⁸
  Crosby SR, Tsigos C, Anderton CC, Gordon C, Young RJ, White A. Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia. 1992;35:868-72.
• ²⁹
  Goldman JE. Regulation of oligodendrocyte differentiation. TINS 1992;15:359-62.
• ³⁰
  Komoly S, Hudson LD, Webster HdeF, Bondy CA. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Nat Acad Sci USA. 1992;89:1894-8.
• ³¹
  Schubert P, Ogata T, Marchini C, Ferroni S, Rudolphi K. Protective mechanisms of adenosine in neurons and glial cells. Ann N Y Acad Sci. 1997a;825:1-10.
• ³²
  Schubert P, Ogata T, Rudolphi K, Marchini C, McRae A, Ferroni S. Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann N Y Acad Sci. 1997b;826:337-47.
• ³³
  Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 1998; 812:97-104.
• ³⁴
  Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scl. 1999;5:126-33.
• ³⁵
  Kammer GA. The adenylate cyclase – cAMP – protein kinase A pathway and regulation of the immune response. Immunol Today. 1988; 9:222-9.

Publication Dates

• Publication in this collection
  Feb 2015

History

• Received
  17 May 2014
• Accepted
  16 Oct 2014